Rapidpurification technology has shown promise in the treatment of acute respiratory infections, but it has been difficult to translate into effective treatments for lung cancer, a new study has found.
Researchers at the University of Nottingham in the UK and University College London in the United Kingdom studied lung cancer patients from the UK’s Covid-19 outbreak and found that rapid purification of water can reduce the risk of infection by as much as 90 percent.
The research was published in the Journal of the American College of Chest Physicians.
“This is a very promising treatment,” lead author Dr. Mark McNeill, who was an investigator in the study, told The Associated Press.
“If you’re a patient and you’re sick with lung disease, the risk is going to be huge.
So it’s important to get the benefit of the treatment in the shortest possible time.
We’ve found that there are a number of advantages to rapid purifying water.”
McNeill and colleagues found that the average lung cancer patient is three to four times more likely to get lung cancer when they drink water containing as much arsenic as a regular person.
The researchers then compared patients’ health with patients who drank regular, non-artificial water.
The arsenic levels were measured using the method of GC-MS, which is a method that uses a large array of analytical techniques to detect small quantities of arsenic.
A common method used in the detection of arsenic in water is to measure its concentration with a GC-mass spectrometer.
Researchers found that arsenic levels in the water were reduced by more than 90 percent when compared to a non-irradiated sample.
McNeill says the study could have an impact on the treatment and management of patients with lung cancers.
“People with lung diseases that are high on the radiographic score are very likely to have cancer that is highly concentrated in the lungs,” McNeill said.
“So we’re looking at a way to manage those patients to make sure they get the treatment that they need and have the best outcome.”